Antioxidant Effect of Ozonated Vegetable Oil and Vitamins in Moderately Active Subjects (ANTIOX001)

Evaluation of the Antioxidant Effect of a Mixture of Ozonated Vegetable Oil and Vitamin Complex (Vitamin K2 and Vitamin B9) in Moderately Active Subjects With "Physical Activity Level" (LAF: 1.70-1.99): Pilot Study

The purpose of this pilot study is to evaluate the antioxidant effect of a nutraceutical formulation based on vegetable oil and vitamin complex (vitamin K2 and vitamin B9) in subjects with the same level of physical activity (LAF 1.70-1.99, normally active or moderately active).

Study Overview

• Status: Completed
• Conditions: Inflammation; Oxidative Stress
• Intervention / Treatment: Dietary supplement: Ozonized vegetable oil with vitamines

Detailed Description

Study design: The pilot study will enroll 20 subjects with physical activity level LAF 1.70-1.99 (normally active or moderately active).

The 20 subjects will be divided into two groups of 10 subjects following randomization. The first group will take the dietary supplement (three capsules per day) for 60 days, while the second group will take a placebo (three capsules per day) for 60 days.

During the treatment period (60 days), the two groups will undergo follow-ups at days 0, 15, 30 and 60 within which clinical and hematochemical examinations will be conducted. At the end of the 60 days, after the wash-out period (two weeks), as per the cross-over design the group previously taking the dietary supplement will be on placebo (three capsules per day) for 60 days, while the group previously taking placebo will take the dietary supplement (three capsules per day) for 60 days. Again, follow-ups will be at 0, 15, 30 and 60 days.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Italy
  • Perugia
    • Corciano, Perugia, Italy, 06073
      • Crabion srl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects of both sexes;
• Aged between 18 and 60 years, naïve to taking antioxidant supplements;
• Absent of chronic diseases and current therapies;
• willing and able to understand and sign an informed consent;
• willing to follow a dietary pattern developed according to the LARN (Reference Intake Levels of Nutrients and Energy for the Italian Population) guidelines that establish reference intake levels for Average Energy Requirement (AR) and Macronutrients (Carbohydrates, Lipids and Protein) for the Italian adult population [LARN Tables*];
• Hematobiochemical examinations in normal range: blood count, lipid status, renal and liver function, inflammatory status (Tnfα, C-reactive protein, ESR), glycemic profile (Fasting blood glucose, HbA1C, insulinemia, Homa Index);
• BMI in the normal range (18-24.99);
• Physical activity level LAF 1.70-1.99 (normally active or moderately active)

Exclusion Criteria:

• Chronic diseases (chronic renal failure, chronic hepatocellular failure, autoimmune diseases, chronic inflammatory bowel disease, diabetes mellitus, end-stage neoplasms, symptomatic chronic ischemic heart disease)
• Severe hypertension;
• High-grade hypercholesterolemia;
• Age < 18 years;
• Poor compliance;
• Intake of dietary supplements containing antioxidants;
• Untreated hypothyroidism;
• Pregnant and lactating women;
• Underweight subjects (BMI ≤18.49);
• Overweight subjects (25≤ BMI ≤30);
• Subjects with obesity (BMI ≥30);
• Subjects with different levels of physical activity: very active (LAF 2.00-2.40) and sedentary (LAF 1.40-1.69).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Supplement; This arm will take dietary supplement	Dietary supplement: Ozonized vegetable oil with vitamines; description: A single capsule is composed by ozonized vegetable oil (75 mg), vitamin K2 (20 mcg), vitamin B9 (130 mcg). The posology is three capsules/day. The time of administration is two months.
Placebo Comparator: Placebo; Placebo will take the placebo	Dietary supplement: Ozonized vegetable oil with vitamines; description: A single capsule is composed by ozonized vegetable oil (75 mg), vitamin K2 (20 mcg), vitamin B9 (130 mcg). The posology is three capsules/day. The time of administration is two months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of hematic oxidative stress by quantifying ROS (CARR U)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up	baseline value before crossover
Evaluation of hematic oxidative stress by quantifying ROS (CARR U)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 15 days of treatment before crossover
Evaluation of hematic oxidative stress by quantifying ROS (CARR U)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 30 days of treatment before crossover
Evaluation of hematic oxidative stress by quantifying ROS (CARR U)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 60 days of treatment before crossover
Evaluation of hematic oxidative stress by quantifying ROS (CARR U)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up	baseline after crossover
Evaluation of hematic oxidative stress by quantifying ROS (CARR U)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 15 days of treatment after crossover
Evaluation of hematic oxidative stress by quantifying ROS (CARR U)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 30 days of treatment after crossover
Evaluation of hematic oxidative stress by quantifying ROS (CARR U)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 60 days of treatment after crossover
Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up	Baseline before crossover
Evaluation of hematic oxidative stress by biological antioxidant potential (umol/l)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 15 days of treatment before crossover
Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 30 days of treatment before crossover
Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 60 days of treatment before crossover
Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up	baseline after crossover
Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 15 days of treatment after crossover
Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 30 days of treatment after crossover
Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l)	Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up	evaluation after 60 days of treatment after crossover

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of hematic inflammatory parameters by quantifying C-Reactive Protein (CRP)	Evaluation of the modulation of inflammatory parameters by C-Reactive Protein (CRP) using mg/dl as unit of measure	baseline value before crossover
Assessment of hematic inflammatory parameters by quantifying C-Reactive Protein (CRP)	Evaluation of the modulation of inflammatory parameters by C-Reactive Protein (CRP) using mg/dl as unit of measure	evaluation after 60 days of treatment before crossover
Assessment of hematic inflammatory parameters by quantifying C-Reactive Protein (CRP)	Evaluation of the modulation of inflammatory parameters by C-Reactive Protein (CRP) using mg/dl as unit of measure	baseline after crossover
Assessment of hematic inflammatory parameters by quantifying C-Reactive Protein (CRP)	Evaluation of the modulation of inflammatory parameters by C-Reactive Protein (CRP) using mg/dl as unit of measure	evaluation after 60 days of treatment after crossover
Assessment of hematic inflammatory parameters by quantifying Erythrocyte Sedimentation Rate (ESR)	Evaluation of the modulation of inflammatory parameters by measuring Erythrocyte Sedimentation Rate (ESR) using mm/h as unit of measure	baseline value before crossover
Assessment of hematic inflammatory parameters by quantifying Erythrocyte Sedimentation Rate (ESR)	Evaluation of the modulation of inflammatory parameters by measuring Erythrocyte Sedimentation Rate (ESR) using mm/h as unit of measure	evaluation after 60 days of treatment before the crossover
Assessment of hematic inflammatory parameters by quantifying Erythrocyte Sedimentation Rate (ESR)	Evaluation of the modulation of inflammatory parameters by measuring Erythrocyte Sedimentation Rate (ESR) using mm/h as unit of measure	baseline after crossover
Assessment of hematic inflammatory parameters by quantifying Erythrocyte Sedimentation Rate (ESR)	Evaluation of the modulation of inflammatory parameters by measuring Erythrocyte Sedimentation Rate (ESR) using mm/h as unit of measure	evaluation after 60 days of treatment after crossover
Assessment of hematic inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfα)	Evaluation of the modulation of inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfα) using pg/mL as unit of measure	baseline value before crossover
Assessment of hematic inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfα)	Evaluation of the modulation of inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfα) using pg/mL as unit of measure	evaluation after 60 days of treatment before crossover
Assessment of hematic inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfα)	Evaluation of the modulation of inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfα) using pg/mL as unit of measure	baseline after crossover
Assessment of hematic inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfα)	Evaluation of the modulation of inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfα) using pg/mL as unit of measure	evaluation after 60 days of treatment after crossover
Assessment of hematic inflammatory parameters by quantifying Cortisol level	Evaluation of the modulation of inflammatory parameters by measuring Cortisol level using μg/dl as unit of measure	baseline value before crossover
Assessment of hematic inflammatory parameters by quantifying Cortisol level	Evaluation of the modulation of inflammatory parameters by measuring Cortisol level using μg/dl as unit of measure	evaluation after 60 days of treatment before crossover
Assessment of hematic inflammatory parameters by quantifying Cortisol level	Evaluation of the modulation of inflammatory parameters by measuring Cortisol level using μg/dl as unit of measure	baseline value after crossover
Assessment of hematic inflammatory parameters by quantifying Cortisol level	Evaluation of the modulation of inflammatory parameters by measuring Cortisol level using μg/dl as unit of measure	evaluation after 60 days of treatment after crossover

Collaborators and Investigators

• Sponsor: S&R Farmaceutici spa
• Investigators: Principal Investigator: Emanuela Floridi, Doctor, Crabion srl

Publications and helpful links

General Publications

• Barbieri E, Sestili P. Reactive oxygen species in skeletal muscle signaling. J Signal Transduct. 2012;2012:982794. doi: 10.1155/2012/982794. Epub 2011 Dec 5.
• Orsavova J, Misurcova L, Ambrozova JV, Vicha R, Mlcek J. Fatty Acids Composition of Vegetable Oils and Its Contribution to Dietary Energy Intake and Dependence of Cardiovascular Mortality on Dietary Intake of Fatty Acids. Int J Mol Sci. 2015 Jun 5;16(6):12871-90. doi: 10.3390/ijms160612871.
• Romero AC. et al. 2013, 'The Exogenous Antioxidants', in J. A. Morales-González (ed.), oxidative Stress and Chronic Degenerative Diseases - A Role for Antioxidants, IntechOpen, London. doi: 10.5772/52490.
• Romeu M, Aranda N, Giralt M, Ribot B, Nogues MR, Arija V. Diet, iron biomarkers and oxidative stress in a representative sample of Mediterranean population. Nutr J. 2013 Jul 16;12:102. doi: 10.1186/1475-2891-12-102.
• Askari G, Ghiasvand R, Feizi A, Ghanadian SM, Karimian J. The effect of quercetin supplementation on selected markers of inflammation and oxidative stress. J Res Med Sci. 2012 Jul;17(7):637-41.
• Buonocore D, Verri M, Giolitto A, Doria E, Ghitti M, Dossena M. Effect of 8-week n-3 fatty-acid supplementation on oxidative stress and inflammation in middle- and long-distance running athletes: a pilot study. J Int Soc Sports Nutr. 2020 Nov 11;17(1):55. doi: 10.1186/s12970-020-00391-4.
• Dhavamani S, Poorna Chandra Rao Y, Lokesh BR. Total antioxidant activity of selected vegetable oils and their influence on total antioxidant values in vivo: a photochemiluminescence based analysis. Food Chem. 2014 Dec 1;164:551-5. doi: 10.1016/j.foodchem.2014.05.064. Epub 2014 May 22.
• El-Hamidi M. Zaher FA. Production of vegetable oils in the world and in Egypt: An overview. Bull Natl Res Cent. 2018, 42, 1-9. doi: 10.1186/s42269-018-0019-0.
• Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr, Tudor-Locke C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011 Aug;43(8):1575-81. doi: 10.1249/MSS.0b013e31821ece12.
• Reid MB. Invited Review: redox modulation of skeletal muscle contraction: what we know and what we don't. J Appl Physiol (1985). 2001 Feb;90(2):724-31. doi: 10.1152/jappl.2001.90.2.724.
• Tan BL, Norhaizan ME. Effect of High-Fat Diets on Oxidative Stress, Cellular Inflammatory Response and Cognitive Function. Nutrients. 2019 Oct 25;11(11):2579. doi: 10.3390/nu11112579.
• Simioni C, Zauli G, Martelli AM, Vitale M, Sacchetti G, Gonelli A, Neri LM. Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging. Oncotarget. 2018 Mar 30;9(24):17181-17198. doi: 10.18632/oncotarget.24729. eCollection 2018 Mar 30.
• Powers SK, Deminice R, Ozdemir M, Yoshihara T, Bomkamp MP, Hyatt H. Exercise-induced oxidative stress: Friend or foe? J Sport Health Sci. 2020 Sep;9(5):415-425. doi: 10.1016/j.jshs.2020.04.001. Epub 2020 May 4.
• Sakellariou GK, Jackson MJ, Vasilaki A. Redefining the major contributors to superoxide production in contracting skeletal muscle. The role of NAD(P)H oxidases. Free Radic Res. 2014 Jan;48(1):12-29. doi: 10.3109/10715762.2013.830718. Epub 2013 Oct 7.
• Powers SK, Ji LL, Kavazis AN, Jackson MJ. Reactive oxygen species: impact on skeletal muscle. Compr Physiol. 2011 Apr;1(2):941-69. doi: 10.1002/cphy.c100054.
• Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, Gargiulo G, Testa G, Cacciatore F, Bonaduce D, Abete P. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018 Apr 26;13:757-772. doi: 10.2147/CIA.S158513. eCollection 2018.
• Mironczuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. Adv Med Sci. 2018 Mar;63(1):68-78. doi: 10.1016/j.advms.2017.05.005. Epub 2017 Aug 17.
• Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006 Oct 18;296(15):1885-99. doi: 10.1001/jama.296.15.1885. Erratum In: JAMA. 2007 Feb 14;297(6):590.
• Misurcova L, Ambrozova J, Samek D. Seaweed lipids as nutraceuticals. Adv Food Nutr Res. 2011;64:339-55. doi: 10.1016/B978-0-12-387669-0.00027-2.
• Yildirim E, Cinar M, Yalcinkaya I, Ekici H, Atmaca N, Guncum E. Effect of cocoa butter and sunflower oil supplementation on performance, immunoglobulin, and antioxidant vitamin status of rats. Biomed Res Int. 2014;2014:606575. doi: 10.1155/2014/606575. Epub 2014 Jul 16.
• Petraru A, Ursachi F, Amariei S. Nutritional Characteristics Assessment of Sunflower Seeds, Oil and Cake. Perspective of Using Sunflower Oilcakes as a Functional Ingredient. Plants (Basel). 2021 Nov 17;10(11):2487. doi: 10.3390/plants10112487.
• Kim JG, Yousef AE, Dave S. Application of ozone for enhancing the microbiological safety and quality of foods: a review. J Food Prot. 1999 Sep;62(9):1071-87. doi: 10.4315/0362-028x-62.9.1071.

Study record dates

Study Major Dates

• Study Start (Actual): September 15, 2022
• Primary Completion (Actual): February 15, 2023
• Study Completion (Actual): March 24, 2023

Study Registration Dates

• First Submitted: September 27, 2022
• First Submitted That Met QC Criteria: October 20, 2022
• First Posted (Actual): October 24, 2022

Study Record Updates

• Last Update Posted (Actual): March 27, 2023
• Last Update Submitted That Met QC Criteria: March 24, 2023
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: inflammation; antioxidant; ozonated sunflower oil
• Additional Relevant MeSH Terms: Pathologic Processes; Inflammation; Physiological Effects of Drugs; Micronutrients; Vitamins
• Other Study ID Numbers: ANTIOX001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No